quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·1221d
PRRelease
Adagio Therapeutics Inc. logo

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

ADGI· Adagio Therapeutics Inc.
Health Care
Original source

Companies

  • ADGI
    Adagio Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 6UpdateMorgan Stanley$6.00
  • Jan 6UpdateMorgan Stanley-
  • Dec 22UpdateJefferies$10.00
  • Dec 15UpdateMorgan Stanley$11.00
  • Dec 15UpdateGuggenheim-
  • Dec 15UpdateStifel$9.00

Related

  • PR1150d
    Invivyd to Participate at Cowen's 43rd Annual Healthcare Conference
  • PR1175d
    Invivyd Announces Changes to Executive Team
  • SEC1200d
    Adagio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • INSIDER1224d
    SEC Form 4 filed by Dabora Rebecca
  • INSIDER1224d
    SEC Form 4 filed by Andersen Jill
  • INSIDER1224d
    SEC Form 4 filed by Schmidt Peter
  • INSIDER1224d
    SEC Form 4 filed by Gowler Jeremy
  • INSIDER1224d
    SEC Form 3 filed by new insider Gowler Jeremy
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022